$ACIU

2 stories mentioning ACIUUpdated 35m ago

Every FINWIRES story that references ACIU, newest first.

Sector Update: Healthcare Stocks Softer Tuesday Afternoon

Healthcare stocks declined Tuesday afternoon with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 0.3%.The iShares Biotechnology ETF (IBB) rose 0.3%.In corporate news, Hims & Hers Health (HIMS) shares fell 1.9%. Q2 results were mixed, with upside in its US business from branded GLP-1 strength and a ramp in testosterone offset by disappointing gross margin and weak free cash flow, Morgan Stanley said.Eli Lilly (LLY) committed to use Veeva Systems' (VEEV) Veeva Vault CRM globally. Lilly shares fell 0.9%, and Veeva added 1%.AC Immune's (ACIU) ACI-7104, for the potential treatment of early-stage Parkinson's disease, received US Food and Drug Administration fast-track designation and investigational new drug clearance. The shares jumped 14%.

$ACIU$HIMS$LLY$VEEV

Wire61d ago

AC Immune to Obtain $4 Million Research Grant From Foundation for Parkinson's Disease Therapy Trial

AC Immune (ACIU) is set to obtain a research grant of $4 million from the Vijay and Marie Goradia Charitable Foundation to support its phase 2 trial evaluating ACI-7104 in early Parkinson's disease, the company said Thursday.The grant will support extending the first part of the trial, and will help assess the long-term safety and efficacy of the active immunotherapy for an additional two years, according to a statement.AC Immune said that the final results of the trial's first part is expected in H2.Price: $2.16, Change: $+0.04, Percent Change: +1.89%

$ACIU

Track with the FINWIRES app suite

FolioX

Track ACIU in your portfolio

WheelAI

Analyze ACIU options with the wheel strategy

StockInsider

See market sentiment on ACIU